186 related articles for article (PubMed ID: 35758870)
1. Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer.
Kanabar D; Goyal M; Kane EI; Chavan T; Kabir A; Wang X; Shukla S; Almasri J; Goswami S; Osman G; Kokolis M; Spratt DE; Gupta V; Muth A
J Med Chem; 2022 Jul; 65(13):8975-8997. PubMed ID: 35758870
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the aryl-triazole of cjoc42 for enhanced gankyrin binding and anti-cancer activity.
Kanabar D; Farrales P; Kabir A; Juang D; Gnanmony M; Almasri J; Torrents N; Shukla S; Gupta V; Dukhande VV; D'Souza A; Muth A
Bioorg Med Chem Lett; 2020 Sep; 30(17):127372. PubMed ID: 32738965
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of 2,5-substituted pyrimidines as small-molecule gankyrin binders.
Kanabar D; Kane EI; Chavan T; Laflamme TM; Suarez E; Goyal M; Gupta V; Spratt DE; Muth A
Future Med Chem; 2024 Feb; 16(3):239-251. PubMed ID: 38205637
[No Abstract] [Full Text] [Related]
4. Resurfaced shape complementary proteins that selectively bind the oncoprotein gankyrin.
Chapman AM; McNaughton BR
ACS Chem Biol; 2014 Oct; 9(10):2223-8. PubMed ID: 25137482
[TBL] [Abstract][Full Text] [Related]
5. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.
Chen J; Bai M; Ning C; Xie B; Zhang J; Liao H; Xiong J; Tao X; Yan D; Xi X; Chen X; Yu Y; Bast RC; Zhang Z; Feng Y; Zheng W
Oncogene; 2016 May; 35(19):2506-17. PubMed ID: 26364616
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell.
Chattopadhyay A; O'Connor CJ; Zhang F; Galvagnion C; Galloway WR; Tan YS; Stokes JE; Rahman T; Verma C; Spring DR; Itzhaki LS
Sci Rep; 2016 Apr; 6():23732. PubMed ID: 27046077
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1β/Iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis.
Su B; Luo T; Zhu J; Fu J; Zhao X; Chen L; Zhang H; Ren Y; Yu L; Yang X; Wu M; Feng G; Li S; Chen Y; Wang H
Hepatology; 2015 Feb; 61(2):585-97. PubMed ID: 25294684
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53.
Chapman AM; McNaughton BR
ACS Chem Biol; 2015 Aug; 10(8):1880-6. PubMed ID: 25955581
[TBL] [Abstract][Full Text] [Related]
9. Discovery of multiple interacting partners of gankyrin, a proteasomal chaperone and an oncoprotein--evidence for a common hot spot site at the interface and its functional relevance.
Nanaware PP; Ramteke MP; Somavarapu AK; Venkatraman P
Proteins; 2014 Jul; 82(7):1283-300. PubMed ID: 24338975
[TBL] [Abstract][Full Text] [Related]
10. The Oncoprotein Gankyrin/PSMD10 as a Target of Cancer Therapy.
Fujita J; Sakurai T
Adv Exp Med Biol; 2019; 1164():63-71. PubMed ID: 31576540
[TBL] [Abstract][Full Text] [Related]
11. Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell Lines.
Taheri T; Jamialahmadi K; Khadijeh F
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3413-3418. PubMed ID: 29286612
[TBL] [Abstract][Full Text] [Related]
12. The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation.
Higashitsuji H; Liu Y; Mayer RJ; Fujita J
Cell Cycle; 2005 Oct; 4(10):1335-7. PubMed ID: 16177571
[TBL] [Abstract][Full Text] [Related]
13. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
Sakurai T; Yada N; Hagiwara S; Arizumi T; Minaga K; Kamata K; Takenaka M; Minami Y; Watanabe T; Nishida N; Kudo M
Cancer Sci; 2017 Oct; 108(10):1996-2003. PubMed ID: 28777492
[TBL] [Abstract][Full Text] [Related]
14. Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity.
Zhen C; Chen L; Zhao Q; Liang B; Gu YX; Bai ZF; Wang K; Xu X; Han QY; Fang DF; Wang SX; Zhou T; Xia Q; Gong WL; Wang N; Li HY; Jin BF; Man JH
Oncogene; 2013 Jul; 32(29):3452-60. PubMed ID: 22890318
[TBL] [Abstract][Full Text] [Related]
15. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells.
Sun W; Ding J; Wu K; Ning BF; Wen W; Sun HY; Han T; Huang L; Dong LW; Yang W; Deng X; Li Z; Wu MC; Feng GS; Xie WF; Wang HY
Hepatology; 2011 Oct; 54(4):1259-72. PubMed ID: 21735473
[TBL] [Abstract][Full Text] [Related]
16. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
[TBL] [Abstract][Full Text] [Related]
17. Structural modification of the aryl sulfonate ester of cjoc42 for enhanced gankyrin binding and anti-cancer activity.
Kanabar D; Farrales P; Gnanamony M; Almasri J; Abo-Ali EM; Otmankel Y; Shah H; Nguyen D; El Menyewi M; Dukhande VV; D'Souza A; Muth A
Bioorg Med Chem Lett; 2020 Feb; 30(4):126889. PubMed ID: 31902711
[TBL] [Abstract][Full Text] [Related]
18. Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.
Jiang Y; Iakova P; Jin J; Sullivan E; Sharin V; Hong IH; Anakk S; Mayor A; Darlington G; Finegold M; Moore D; Timchenko NA
Hepatology; 2013 Mar; 57(3):1098-106. PubMed ID: 23172628
[TBL] [Abstract][Full Text] [Related]
19. Chronic Microcystin-LR Exposure Induces Hepatocarcinogenesis via Increased Gankyrin in Vitro and in Vivo.
He L; Huang Y; Guo Q; Zeng H; Zheng C; Wang J; Chen JA; Wang L; Shu W
Cell Physiol Biochem; 2018; 49(4):1420-1430. PubMed ID: 30205410
[TBL] [Abstract][Full Text] [Related]
20. Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.
Kim YH; Kim JH; Choi YW; Lim SK; Yim H; Kang SY; Chung YS; Lee GY; Park TJ
Exp Mol Pathol; 2013 Apr; 94(2):360-5. PubMed ID: 23276718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
